JP Morgan 2022 – Beam and Mammoth hook big pharma partners
Beam signs Pfizer up for $300m up front, while Mammoth’s deal with Bayer is worth a more modest $40m.
Investors back Quell’s Treg approach
Quell should soon join Sangamo in the clinic, while a number of engineered Treg players are at the preclinical stage.
Neurocrine gets selective in schizophrenia
The group’s deal with Sosei will see it compete with Karuna and Cerevel.
Vertex goes small with Mammoth deal
Vertex strikes yet another gene editing deal, this time with the “ultra-small” Crispr specialist Mammoth.
Boehringer takes a different approach in cystic fibrosis gene therapy
Deals this week with a UK consortium and Oxford Biomedica see the group bet on lentiviral vectors.
Another gene therapy safety scare hits
The clinical hold for Biomarin’s phenylketonuria project comes on the heels of an FDA adcom to discuss gene therapy toxicity.
